Astrazeneca Plc ADR (AZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Sales | 15,191,000 | 14,457,000 | 13,588,000 | 14,891,000 | 13,565,000 |
| Cost of Goods | 2,801,000 | 2,473,000 | 2,241,000 | 2,725,000 | 3,081,000 |
| Gross Profit | 12,390,000 | 11,984,000 | 11,347,000 | 12,166,000 | 10,484,000 |
| Operating Expenses | 8,807,000 | 8,476,000 | 7,673,000 | 10,130,000 | 8,378,000 |
| Operating Income | 3,583,000 | 3,508,000 | 3,674,000 | 2,036,000 | 2,106,000 |
| Interest Expense | 434,000 | 439,000 | 349,000 | 429,000 | 457,000 |
| Other Income | 95,000 | 58,000 | 77,000 | 59,000 | 179,000 |
| Pre-tax Income | 3,244,000 | 3,127,000 | 3,402,000 | 1,666,000 | 1,828,000 |
| Income Tax | 709,000 | 679,000 | 481,000 | 166,000 | 395,000 |
| Net Income Continuous | 2,535,000 | 2,448,000 | 2,921,000 | 1,500,000 | 1,433,000 |
| Minority Interests | 2,000 | -2,000 | N/A | 1,000 | 4,000 |
| Net Income | $2,533,000 | $2,450,000 | $2,921,000 | $1,499,000 | $1,429,000 |
| EPS Basic Total Ops | 0.82 | 0.79 | 0.94 | 0.49 | 0.46 |
| EPS Basic Continuous Ops | 0.82 | 0.79 | 0.94 | 0.48 | 0.46 |
| EPS Diluted Total Ops | 0.81 | 0.79 | 0.94 | 0.48 | 0.46 |
| EPS Diluted Continuous Ops | 0.81 | 0.79 | 0.94 | 0.48 | 0.46 |
| EPS Diluted Before Non-Recurring Items | 1.19 | 1.09 | 1.24 | 1.05 | 1.04 |
| EBITDA(a) | $5,132,000 | $4,897,000 | $4,958,000 | $4,373,000 | $3,923,000 |